400% share price surge! Is it too late to buy shares in Synairgen?

After the rapid 400% share price rise you may be wondering if it is too late to buy shares in Synairgen. Here’s what I think.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Synairgen (LON:SNG) is a drug company specialising in therapies for asthma and COPD. This morning the Synairgen share price surged over 400% after it announced positive results on a recent clinical trial relating to a new treatment for Covid-19.

The £287m company has been listed on the FTSE AIM All-Share index since 2004. Today’s share price surge took it skyrocketing past its IPO high of £1.64 a share. Is it now too late to buy shares in this exciting biotech company?

Why the price surge?

The clinical trial moving the Synairgen share price was based on its SGN001 therapy. This is a treatment designed to reduce the most serious aspects of Covid-19 in hospitalised patients. It involves the use of a protein called interferon beta that is naturally found in the body but suppressed by the coronavirus.

By inhaling this protein, the patient experiences relief and a reduction in breathlessness. The clinical trial resulted in a 79% reduction in patients developing severe disease requiring ventilation. It also showed patients were 2 to 3 times more likely to make a much better recovery. It should be noted these results have not yet been published in a peer-reviewed journal and further analysis will be needed.

A few years ago, the interferon beta therapy developed by Synairgen was being used in partnership with big pharma giant AstraZenecaAZN pulled out of the partnership when an asthma trial failed, which put the Synairgen share price into free-fall. However, Synairgen always maintained the drug therapy had potential and retained full rights after AstraZeneca pulled out. Today’s news is a major comeback from that previous disappointment.

Has the Synairgen share price got further to climb? 

With AIM shares there is always the risk that things won’t go as planned. Buying shares in pharmaceutical companies also always comes with an element of risk. Biotech and pharma is a tightly regulated industry filled with speculation, and managing cash flow can be tricky. However, this is a fantastic development for Synairgen. I think today’s news gives it positive attention that will stand it in good stead for some time to come. Synairgen was previously backed by Neil Woodford, who added it to his former UK equity fund.

When dealing with pharmaceutical treatments there are many regulatory hoops to jump through. But with the Covid-19 pandemic, everyone is eager for anything that will help bring it under control. For this reason, I don’t think it is necessarily too late to buy shares in Synairgen. Certainly, those shareholders that got in early on a speculative buy will be feeling very pleased that they did so.

This is still a risky buy but could be an exciting addition to a diversified portfolio looking for growth opportunities. I think the Synairgen share price has further to climb.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kirsteen has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

View of Tower Bridge in Autumn
Investing Articles

The FTSE 100 is closing in on 8,000 points! Here’s what I’m buying before it’s too late!

As the FTSE 100 keeps gaining momentum, this Fool is on the lookout for bargains. Here's one stock he'd willingly…

Read more »

Investing Articles

3 ideas to help investors aim for a million-pound Stocks & Shares ISA

The UK has a growing number of Stocks and Shares ISA millionaires, and this plan may be one of the…

Read more »

Illustration of flames over a black background
Investing Articles

2 red-hot UK growth stocks to consider buying in April

These two growth stocks are performing well, but can they continue to deliver for investors through 2024 and beyond?

Read more »

Charticle

Is JD Sports Fashion one of the FTSE 100’s best value stocks? Here’s what the charts say!

The JD Sports Fashion share price remains a wild ride during the first quarter. Could it be one of the…

Read more »

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »